相关实验视频
Updated: Jul 11, 2026

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
在加拿大曼尼托巴省使用糖原合成酶-3β抑制剂和前列腺癌发病率:基于人口的嵌套病例对照研究
Christiaan H Righolt1, Emrah Sever2, Salaheddin M Mahmud1
1Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, S108-750 Bannatyne Avenue, Winnipeg, MB R3E 0W2, Canada; College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB R3E 0T5, Canada.
Cancer epidemiology
|January 15, 2025
概括
糖原合成酶激酶-3β抑制剂 (GSK3Is) 在曼尼托巴的一项研究中显示,可能降低前列腺癌 (PC) 的风险. 然而,对于奥兰zapine和famotidine等特定药物的发现,由于潜在的混因素,需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 对糖原合成酶激酶-3β抑制剂 (GSK3Is) 类对前列腺癌 (PC) 的影响的理解有限.
- 之前的研究报告了关于酸对PC的影响的混合结果.
- 在定义的群体中需要进行全面分析.
研究的目的:
- 调查GSK3I使用与前列腺癌风险之间的关联.
- 分析特定的GSK3I (,氨酸,奥兰zapine, famotidine) 对PC的影响.
- 检查这些关联与双相情感障碍和症状有关.
主要方法:
- 在加拿大曼尼托巴 (Manitoba) 进行了嵌套病例控制研究 (2000 - 2018年).
- 根据年龄,期间和药物数据,匹配了11,189名PC患者和55,728名无癌症对照.
- 用于分析GSK3I使用的条件后勤回归,包括剂量和持续时间.
主要成果:
- 总体而言,使用GSK3I与PC风险降低有关 (OR=0.81).
- 法莫蒂丁 (OR=0.87) 和奥兰扎平 (OR=0.72) 显示出一种潜在的保护作用.
- 酸在患者中显示出可能的保护作用 (OR=0.35),但在双相情感障碍患者中没有.
结论:
- 对 olanzapine 和 famotidine 的潜在PC 保护作用缺乏剂量反应证据,这表明可能有机会或混.
- 酸与患者PC风险降低的相关性需要进行更大规模的研究来确认.
- 需要进一步的研究来澄清GSK3Is在前列腺癌预防中的作用.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
